Versant Ventures

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China.

Tentarix Biotherapeutics is focused on developing innovative protein therapeutics that address significant challenges in the treatment of cancer, autoimmune diseases, and other medical conditions. The company utilizes a protein engineering platform that employs synthetic biology to create multispecific binding molecules with unique combined bioactivities. By leveraging fully human antibody variable domains, Tentarix aims to enhance specificity and therapeutic activity, offering clinicians new approaches to treatment that were previously unattainable.

858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.

Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.

Presbyopia Therapies LLC moves forward with development of its Liquid Vision drops, a temporary presbyopia-correcting therapeutic designed to last five hours or longer.

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. The company was founded in 2019 and headquartered in Alberta, Canada.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, that specializes in the discovery, development, and commercialization of innovative therapies for ocular surface diseases. Founded in 2015, the company is primarily focused on its lead product candidate, OC-01, a nicotinic acetylcholine receptor agonist currently undergoing Phase III clinical trials for the treatment of dry eye disease. This condition, which affects over 30 million Americans, is characterized by a chronic lack of sufficient tears, leading to discomfort and potential vision problems. OC-01 is developed as a nasal spray and aims to restore tear film homeostasis by activating the trigeminal parasympathetic pathway, thereby stimulating natural tear production. Additionally, the company is exploring the use of OC-01 for neurotrophic keratitis, further expanding its therapeutic potential in ocular health.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.

Gotham Therapeutics is a biotechnology company based in New York that focuses on developing a novel class of drugs aimed at targeting epitranscriptomics machinery. Established in 2017, the company seeks to create new treatment options for patients afflicted with various conditions, including cancers, autoimmune disorders, and neurodegenerative diseases. By altering the activity of proteins that modify messenger ribonucleic acid (mRNA), Gotham Therapeutics aims to advance therapeutic strategies and improve patient outcomes in these challenging medical areas.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Pandion Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for autoimmune diseases. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials to address various autoimmune and inflammatory conditions. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to facilitate tissue-selective immunomodulation in the gastrointestinal tract. PT001 combines a PD-1 agonist with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM), while PT002 merges an IL-2 mutein effector with a MAdCAM-binding module. The company has also established a collaboration with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. Headquartered in Watertown, Massachusetts, Pandion Therapeutics aims to create effective and safe treatments to improve patient outcomes in the field of autoimmune disorders.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California. The company specializes in developing innovative therapeutics to address unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Its lead drug candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for CHB. Aligos is also advancing several other candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist for NASH. The company's strategy leverages the extensive expertise of its team in liver disease and viral hepatitis to develop targeted antiviral therapies and expedite its drug development pipeline.

Jnana Therapeutics Inc. is a Boston-based company founded in 2016 that operates a drug discovery platform centered on solute carrier (SLC) transporters. The company focuses on key disease pathways related to immunometabolism, lysosomal function, and mucosal defense, targeting areas such as immuno-oncology, inflammatory disorders, and neurological diseases. By leveraging its innovative approach, Jnana Therapeutics aims to discover and develop transformative medicines that address significant medical needs and improve patient outcomes.

Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company based in Princeton, New Jersey, that specializes in the discovery, development, and commercialization of innovative therapies for ocular surface diseases. Founded in 2015, the company is primarily focused on its lead product candidate, OC-01, a nicotinic acetylcholine receptor agonist currently undergoing Phase III clinical trials for the treatment of dry eye disease. This condition, which affects over 30 million Americans, is characterized by a chronic lack of sufficient tears, leading to discomfort and potential vision problems. OC-01 is developed as a nasal spray and aims to restore tear film homeostasis by activating the trigeminal parasympathetic pathway, thereby stimulating natural tear production. Additionally, the company is exploring the use of OC-01 for neurotrophic keratitis, further expanding its therapeutic potential in ocular health.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.

Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

BlueRock Therapeutics LP is a biotechnology company focused on developing engineered cell therapies utilizing its CELL+GENE platform. Founded in 2016 and headquartered in Cambridge, Massachusetts, with additional offices in New York and Toronto, the company specializes in induced pluripotent stem cell (iPSC) therapies aimed at treating various diseases, particularly in the fields of neurology, cardiology, and immunology. One of its key initiatives involves regenerating heart muscle in patients who have experienced heart attacks or suffer from chronic heart failure, addressing significant health challenges. BlueRock also offers stable master cell banks, including healthy donor cells and methods for immune evasion, to support its therapeutic development efforts. As of September 2019, BlueRock operates as a subsidiary of Bayer Aktiengesellschaft.

Kyras Therapeutics Inc. is a biotechnology company established in 2015 and headquartered in New York, New York. The company focuses on developing innovative drugs aimed at treating incurable cancers and developmental disorders. A significant portion of its research targets cancers associated with mutations in RAS genes, which are implicated in over 30 percent of all human cancers, including a high prevalence in pancreatic, colorectal, and lung cancers. Through its specialized approach, Kyras Therapeutics aims to address critical unmet medical needs in oncology and other areas of health.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, specializing in the discovery and development of innovative anti-cancer drugs. Founded in 2011, the company focuses on therapies that target lipid kinase (PI3K) and mTOR, both of which are established drug targets in oncology. PIQUR has developed a robust pipeline of compounds, including its lead product, bimiralisib, which aims for dual inhibition of the PI3K/mTOR pathway. The company's mission is to create breakthrough targeted medicines for oncology and dermatology, addressing the treatment of various cancers and genetic diseases. With a secured patent portfolio protecting many of its chemical compounds, PIQUR Therapeutics is dedicated to enhancing the quality of life for cancer patients through advanced therapeutic options.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.

CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, specializing in the discovery and development of innovative anti-cancer drugs. Founded in 2011, the company focuses on therapies that target lipid kinase (PI3K) and mTOR, both of which are established drug targets in oncology. PIQUR has developed a robust pipeline of compounds, including its lead product, bimiralisib, which aims for dual inhibition of the PI3K/mTOR pathway. The company's mission is to create breakthrough targeted medicines for oncology and dermatology, addressing the treatment of various cancers and genetic diseases. With a secured patent portfolio protecting many of its chemical compounds, PIQUR Therapeutics is dedicated to enhancing the quality of life for cancer patients through advanced therapeutic options.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Founded in 2011, Inception Sciences is a small molecule pharmaceutical incubator. Their focus is on creating high-value therapies with transformative potential to address diseases and disorders with significant unmet needs. Through partnerships with academic experts, they are translating biological insights into highly-targeted, novel drugs. Their team has a proven track record of drug discovery, having played pivotal roles in the discovery of clinical-stage compounds for the treatment of fibrosis, asthma, and COPD at Amira Pharmaceuticals, and of several high-profile drugs at Merck.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular diseases and conditions using its proprietary bioresorbable hydrogel technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for managing post-surgical ocular pain and inflammation, as well as allergic conjunctivitis, and is currently in trials for treating dry eye diseases. Other key products in development include OTX-TP, an intracanalicular insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant also targeting intraocular pressure. Additionally, Ocular Therapeutix is exploring various preclinical programs to address acute ocular pain, post-operative inflammation, and other ophthalmic conditions. The company has a strategic collaboration with Regeneron Pharmaceuticals to utilize its hydrogel technology in conjunction with Regeneron’s VEGF-targeting compounds for retinal disease treatments. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions. Based in Burlington, Massachusetts, it offers ZILRETTA, an intra-articular injection specifically designed for managing osteoarthritis pain in the knee. The company is also developing FX201, a gene therapy aimed at promoting the production of an anti-inflammatory protein for knee osteoarthritis pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Since its founding in 2007, Flexion Therapeutics has collaborated with pharmaceutical and biotechnology firms to advance its drug candidates through clinical trials, thereby enhancing the therapeutic portfolios of its partners.

Cerephex is a company developing its proprietary RINCE technology for treatment applications involving noninvasive brain stimulation. Cerephex is currently engaged in development activities aimed at gaining FDA approval of its NeuroPoint device for the management of fibromyalgia, a chronic pain condition that involves abnormal central pain processing mechanisms.

Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b, which is currently in Phase 3 trials for gastric and gastroesophageal junction cancers. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein aimed at enhancing T cell co-stimulation. Additionally, Cabiralizumab, which targets the colony stimulating factor-1 receptor, is being tested in Phase Ia/Ib trials in combination with Opdivo for cancer treatment. Five Prime also has BMS-986258, an anti-TIGIT antibody in Phase 1/2 trials. The company employs a unique ProScreen Engine that enables efficient production and screening of therapeutic proteins, allowing for a more comprehensive approach than traditional methods. Five Prime has established collaborations and licensing agreements with several prominent pharmaceutical companies, enhancing its research capabilities and market reach.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular diseases and conditions using its proprietary bioresorbable hydrogel technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for managing post-surgical ocular pain and inflammation, as well as allergic conjunctivitis, and is currently in trials for treating dry eye diseases. Other key products in development include OTX-TP, an intracanalicular insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant also targeting intraocular pressure. Additionally, Ocular Therapeutix is exploring various preclinical programs to address acute ocular pain, post-operative inflammation, and other ophthalmic conditions. The company has a strategic collaboration with Regeneron Pharmaceuticals to utilize its hydrogel technology in conjunction with Regeneron’s VEGF-targeting compounds for retinal disease treatments. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular diseases and conditions using its proprietary bioresorbable hydrogel technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for managing post-surgical ocular pain and inflammation, as well as allergic conjunctivitis, and is currently in trials for treating dry eye diseases. Other key products in development include OTX-TP, an intracanalicular insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant also targeting intraocular pressure. Additionally, Ocular Therapeutix is exploring various preclinical programs to address acute ocular pain, post-operative inflammation, and other ophthalmic conditions. The company has a strategic collaboration with Regeneron Pharmaceuticals to utilize its hydrogel technology in conjunction with Regeneron’s VEGF-targeting compounds for retinal disease treatments. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

Flexion Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for musculoskeletal conditions. Based in Burlington, Massachusetts, it offers ZILRETTA, an intra-articular injection specifically designed for managing osteoarthritis pain in the knee. The company is also developing FX201, a gene therapy aimed at promoting the production of an anti-inflammatory protein for knee osteoarthritis pain relief, and FX301, a NaV1.7 inhibitor intended for post-operative pain management. Since its founding in 2007, Flexion Therapeutics has collaborated with pharmaceutical and biotechnology firms to advance its drug candidates through clinical trials, thereby enhancing the therapeutic portfolios of its partners.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular diseases and conditions using its proprietary bioresorbable hydrogel technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for managing post-surgical ocular pain and inflammation, as well as allergic conjunctivitis, and is currently in trials for treating dry eye diseases. Other key products in development include OTX-TP, an intracanalicular insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant also targeting intraocular pressure. Additionally, Ocular Therapeutix is exploring various preclinical programs to address acute ocular pain, post-operative inflammation, and other ophthalmic conditions. The company has a strategic collaboration with Regeneron Pharmaceuticals to utilize its hydrogel technology in conjunction with Regeneron’s VEGF-targeting compounds for retinal disease treatments. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.

Ambrx is a biopharmaceutical company headquartered in La Jolla, California, that specializes in developing engineered precision biologics using a proprietary technology platform to incorporate synthetic amino acids into proteins. The company focuses on creating protein therapeutics that enhance potency, reduce dosing frequency, and improve drug homogeneity. Its development pipeline includes antibody drug conjugates (ADCs), bi-specific product candidates, and long-acting protein therapeutics, alongside various early-stage programs. Ambrx has established collaborations with MabSpace Biosciences for ADC development in oncology, BeiGene for the commercialization of biologic drugs, and NovoCodex Biopharmaceuticals for the advancement of ARX305, an ADC targeting CD70 positive cancers. Founded in 2003, the company aims to innovate and expand the capabilities of biologic therapies.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. On May 4, 2010 Cadence resubmitted a New Drug Application for its investigational product candidate, OFIRMEVTM (acetaminophen) injection for the treatment of pain and fever in adults and children. The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) action date for OFIRMEV of November 4, 2010.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular diseases and conditions using its proprietary bioresorbable hydrogel technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for managing post-surgical ocular pain and inflammation, as well as allergic conjunctivitis, and is currently in trials for treating dry eye diseases. Other key products in development include OTX-TP, an intracanalicular insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant also targeting intraocular pressure. Additionally, Ocular Therapeutix is exploring various preclinical programs to address acute ocular pain, post-operative inflammation, and other ophthalmic conditions. The company has a strategic collaboration with Regeneron Pharmaceuticals to utilize its hydrogel technology in conjunction with Regeneron’s VEGF-targeting compounds for retinal disease treatments. Founded in 2006, Ocular Therapeutix is headquartered in Bedford, Massachusetts.

PhaseRx is a biopharmaceutical company based in Seattle that focuses on the development of innovative therapies for inherited enzyme deficiencies in the liver. Utilizing its proprietary Hybrid messenger RNA technology platform, PhaseRx aims to provide intracellular enzyme replacement therapy (i-ERT) by enabling the synthesis of essential enzymes directly within cells. The company is developing a portfolio of products targeting specific urea cycle disorders, including ornithine transcarbamylase deficiency, argininosuccinate lyase deficiency, and argininosuccinate synthetase deficiency. Founded by a team with expertise from the University of Washington and Fred Hutchinson Cancer Research Center, PhaseRx leverages novel polymer technology for the delivery of therapeutic agents, including siRNA and other macromolecular therapeutics.

APT Pharmaceuticals is a drug development company focused on repurposing well-characterized drugs for under-served populations. APT’s initial focus is on the pulmonary delivery of treatments for serious lung diseases.

MedManage Systems is an online provider of prescription drug sampling solutions. The company's Samples On Demand service facilitates connections between pharmaceutical manufacturers and healthcare providers through a network of physician portals. This service enables users to access medication samples conveniently and efficiently, improving the distribution of pharmaceutical products. By offering on-demand access to drug samples, MedManage enhances the ability of pharmaceutical brands to reach their customers while streamlining the sampling process for healthcare professionals.

CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Trius Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative antibiotics aimed at treating life-threatening infections. The company has successfully completed two Phase 3 clinical trials for its lead product, Tedizolid Phosphate, a second-generation oxazolidinone designed for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). As bacterial resistance to existing antibiotics continues to rise, the need for new therapeutics to combat multi-drug resistant infections becomes increasingly urgent. Trius Therapeutics is led by a skilled management team with extensive experience in drug development and regulation, contributing to the company's efforts to address critical healthcare challenges posed by antibiotic resistance.

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Their discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Ambrx is a biopharmaceutical company headquartered in La Jolla, California, that specializes in developing engineered precision biologics using a proprietary technology platform to incorporate synthetic amino acids into proteins. The company focuses on creating protein therapeutics that enhance potency, reduce dosing frequency, and improve drug homogeneity. Its development pipeline includes antibody drug conjugates (ADCs), bi-specific product candidates, and long-acting protein therapeutics, alongside various early-stage programs. Ambrx has established collaborations with MabSpace Biosciences for ADC development in oncology, BeiGene for the commercialization of biologic drugs, and NovoCodex Biopharmaceuticals for the advancement of ARX305, an ADC targeting CD70 positive cancers. Founded in 2003, the company aims to innovate and expand the capabilities of biologic therapies.

MedManage Systems is an online provider of prescription drug sampling solutions. The company's Samples On Demand service facilitates connections between pharmaceutical manufacturers and healthcare providers through a network of physician portals. This service enables users to access medication samples conveniently and efficiently, improving the distribution of pharmaceutical products. By offering on-demand access to drug samples, MedManage enhances the ability of pharmaceutical brands to reach their customers while streamlining the sampling process for healthcare professionals.

Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.